The anti-tumor properties of two tumstatin peptide fragments in human gastric carcinoma

Yingjie Li1,*, Li-chun Sun2,*, Yan He3,*, Xing-han Liu4, Miao Liu3, Qi-min Wang3, Xiao-ming Jin3,*

1Department of Pathology, Second Hospital of Harbin Medical University, China; 2Department of Medicine Oncology, Tumor Hospital of Harbin Medical University, China; 3Department of Pathology, Harbin Medical University, China; 4Department of Biochemistry, Harbin Medical University, Harbin 150081, China

Aim: The aim was to study the anti-tumor activities and mechanisms of two synthetic peptide fragments of tumstatin (alpha3 (IV) NC1 domain) in human gastric carcinoma cells in vitro and in vivo.

Methods: MTT assay and cell cycle assay were used to study the anti-tumor and anti-angiogenic activities of two peptide fragments in vitro. Apoptosis induced by the two peptide fragments was demonstrated by TUNEL assay and morphological observation. The orthotopic tumor model was established to investigate the activities of two peptide fragments in vivo. Intratumor vascularization and the expressions of VEGF, bFGF, Fas, FasL, Bax, Bcl-2, and caspase 3 were determined using immunohistochemistry and Western blot analysis.

Results: Peptide 19 inhibited SGC-7901 proliferation and induced apoptosis both in vitro and in vivo. Notably, peptide 21 suppressed the proliferation of HUVEC-12 cells in vitro. Each peptide arrested both cell lines at the G0/G1 phase of the cell cycle, and they also synergistically suppressed in vitro and in vivo tumor growth. Immunohistochemistry and Western blot analysis revealed the strong expression of Fas, FasL and caspase 3 in orthotopic tumor tissues treated with peptide 19 alone or in combination with peptide 21. Decreased expressions of VEGF and bFGF and decreased microvessel density (MVD) in orthotopic tumor tissues were seen in mice treated with peptide 21 alone or in combination with peptide 19.

Conclusion: Two tumstatin peptide fragments facilitate two unique antitumor activities. Thus, they are drug candidates in the treatment of gastric carcinoma.

Keywords: tumstatin peptide; anti-cancer drug; apoptosis; angiogenesis

Introduction

Angiogenesis, the formation of new capillaries from pre-existing blood vessels, is generally suppressed in healthy adult organisms and is turned on temporarily in such settings as the female reproductive cycle or during tissue repair processes. However, uncontrolled angiogenesis is associated with a number of pathological disorders, including diabetic retinopathy, rheumatoid arthritis, and tumor growth and metastasis[6, 3]. Optimal tumor growth beyond 1 mm of volume is not possible without neovascularization[1, 3-5]. Moreover, tumors metastasize into other organs via newly formed blood vessels[3, 6]. It is thought that angiogenesis is maintained through a delicate balance between growth factors and inhibition factors.

Tumstatin is an endogenous angiogenesis inhibitor that is derived from type IV collagen. Tumstatin is the noncollagenous domain of type α3 (IV) collagen, a basement membrane collagen found in kidney, lung, testis, and other vascular basement membranes[7]. Tumstatin inhibits angiogenesis by inducing apoptosis and inhibits endothelial cell proliferation through its binding to αvβ3 integrin, leading to suppression of cap-dependent protein translation[8-10]. Maeshima et al[11] used deletion mutagenesis to demonstrate that the anti-angiogenic activity of tumstatin is localized to amino acids 54–132. Subsequently, the anti-angiogenic activity was localized to a 25 amino acid region encompassing amino acids 74–98 (T7-peptide), which contains the entire anti-angiogenic activity associated with tumstatin[12]. The region is distinct from the 185 to 203 region that is responsible for the anti-tumor activity of tumstatin[6, 13]. A synthetic peptide encompassing residues 183–205 of the NCI domain of the α3 [IV] chain specifically inhibited activation of polymorphonuclear leukocytes[14]. This peptide binds to an integrin complex, promotes adhesion and chemotaxis, and inhibits proliferation of various human cancer
Surprisingly, there has been a lack of research on the use of tumstatin for the treatment of gastric tumors, considering its potential for inhibiting angiogenesis and tumor growth in gastric tumor models. This potential is suggested by studies on experimental tumor models of malignant melanoma, bronchopulmonary carcinoma, and malignant glioma. The present experiments were designed to demonstrate the \textit{in vitro} and \textit{in vivo} antitumor properties of two synthetic tumstatin peptides: peptide 19, which corresponds to residues 185–203 of the NC1 domain of the α3 [IV] chain, and peptide 21, a T7 mutant, in human gastric carcinoma cells. We also explored the different mechanisms of antitumor activities for these two synthetic tumstatin peptides. The combination of peptide 19 with peptide 21 was also explored for improved antitumor efficacy.

\textbf{Materials and methods}

\textbf{Synthetic peptides}

The NC1α3 (IV) (185–203) peptide 19, CNYYSNSFYFWLASLNPER; the corresponding scrambled peptide, YAPLWNRSSEFENSLNYSCL; and peptide 21, MPFLFCNVNDCVNFASRNDYS, were purchased from Multiple Peptide Synthesis (San Diego, CA) and Syn Pep Corp (Dublin, CA).

\textbf{Cell lines and cell culture}

Human gastric cancer SGC-7901 cells (Shanghai Cell-biological Institute, Chinese Academy of Sciences) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (10% FBS-DMEM) and 2 U/mL of penicillin-streptomycin mixture and incubated in 5% CO\textsubscript{2}-95% air at 37°C. Human umbilical vein endothelial cells HUVEC-12 (Shanghai Cell-biological Institute, Chinese Academy of Sciences) were grown in Endothelial Cell Medium-2 supplemented with 2% fetal bovine serum, R\textsuperscript{2}-IGF-I, hydrocortisone, ascorbic acid, hFGF, VEGF, hEGF, GA-1000, and heparin as recommended by the manufacturer. All cells were maintained at 37°C in 5% CO\textsubscript{2}.

\textbf{MTT assay}

SGC-7901 cells and HUVEC-12 cells were trypsinized, seeded at 1×10\textsuperscript{4} cells/well in 96-well plates, and treated with peptide 19, peptide 21, and the two peptides together at various concentrations (0, 15, 30, 45, and 60 μg/mL). Twenty-four hours later, the effects on cell growth were examined by MTT assay: 20 μL of MTT (Sigma Co) solution (5 mg/L in PBS) was added to each well, and the cells were incubated for 4 h at 37°C. The adherent cells were subsequently solubilized with 150 μL dimethyl sulfoxide (DMSO). The absorbance (OD) at 570 nm was recorded using an ELISA reader (Bio-Rad). The inhibition rate of cell proliferation was calculated by the following formula: Inhibition rate (%)=(OD\textsubscript{control} − OD\textsubscript{treated})/OD\textsubscript{control}.

\textbf{TUNEL assay}

In brief, SGC-7901 cells were treated with control peptide (34 μg/mL), peptide 19 (34 μg/mL), peptide 21 (34 μg/mL) or peptide 19 (17 μg/mL) and peptide 21 (17 μg/mL) together. After 48 h the number of apoptotic cells was determined using the in situ cell Death Detection kit from Roche Diagnostics (Mannheim, Germany) following the manufacturer’s instructions. The apoptotic cells (fluorescent green staining) were counted under a fluorescence microscope. The apoptotic index was defined by the percentage of fluorescent green cells among the total number of cells in each sample. Three fields with 100 cells per field were randomly counted for each sample.

\textbf{Transmission electron microscopy}

For electron microscope analysis of apoptosis, pretreated SGC-7901 cells and HUVEC-12 cells were fixed in 1% glutaraldehyde and 4% paraformaldehyde in PBS, postfixed in 1% osmium tetroxide in PBS, dehydrated and subsequently embedded in epoxy resin. Ultrathin sections (80 nm) were stained with uranyl and lead acetates and examined under a Hitachi H-600 electron microscope at 80 kV (Hitachi, Tokyo, Japan).

\textbf{Cell cycle assay}

SGC-7901 cells and HUVEC-12 cells were treated with peptide 19 (34 μg/mL), peptide 21 (34 μg/mL) or peptide 19 (17 μg/mL) and peptide 21 (17 μg/mL) together. After 24 h of incubation, the cells were washed in PBS and fixed in 70% ethanol overnight at 4°C. Propidium iodine (10 g/mL) supplemented with RNase A (200 g/mL) was added to the cells for 30 min (at 37°C) prior to FACS analysis.

\textbf{Animals}

Five- to six-week-old female nude athymic BALB/c nu/nu mice were purchased from Beijing Wei Tong Li Hua Laboratory Animal Centre (qualified certificate No SCXK (jing) 2002-2003). They were kept under specific pathogen-free conditions and fed autoclaved pellets and water \textit{ad libitum}. The general health status of the animals was monitored daily. All experiments were carried out with the approval of the Institutional Ethical Committee for Animal Experiments of Heilongjiang Cancer Center Research Institute.

\textbf{Orthotopic human gastric cancer xenografts}

After ip injection of 0.4 mL SGC-7901 cells at a concentration of 5×10\textsuperscript{6}/mL, nude mice developed peritoneal carcinomatosis similar to that of advanced gastric cancer. When nude mice developed massive ascites production, the malignant ascite cells were taken to culture \textit{in vitro}. Following their culture, 0.2 mL of the malignant ascites cells at a concentration of 5×10\textsuperscript{7}/mL was injected hypodermically into another mouse. The tumors were measured using Vernier calipers, and the volume was calculated using the standard formula (length×width\textsuperscript{2}×0.52)\textsuperscript{[10]} The tumors were allowed to grow to about 100 mm\textsuperscript{3}. Mice were anesthetized with 2.5% avertin and the tumors were resected aseptically; the tumor tissue was subsequently cut into smaller pieces of about 1–2 mm\textsuperscript{3}. One piece of this tumor was implanted on the back of another anes-
Intratumor vascularization was examined by immunohistochemical analysis as described previously[18]. The sections were stained with anti-CD34 Ab (at 1:100 dilution, Sigma Co.) and a second peroxidase-conjugated goat anti-rat IgG Ab (1:100 dilution, Santa Cruz biotechnology). Immunoperoxidase staining was carried out using a Simplestain Macro kit (Nichirei, Tokyo, Japan). The density of microvessels was quantified by first scanning the tumor at low power and identifying five areas at the tumor periphery that contained the maximum number of discrete microvessels and then counting the individual microvessels.

Western blot analysis

Tumor tissues were lysed with a hand-held homogenizer using lysis buffer (10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L DTT/1 mmol/L NaF/0.5% NP-40/0.5 mmol/L PMSF/0.2 mmol/L sodium orthovanadate/2 μg/mL of aprotinin, leupeptin and pepstatin). Lysates were incubated at 4°C for 20 min with rotation. After centrifugation at 14,000 r/min (20800×g) for 12 min, the supernatants were collected and boiled in loading buffer, separated by SDS-PAGE, and transferred onto a nitrocellulose membrane. Membranes were blocked with 5% (w/v) milk/PBS/0.1% Tween 20. Immunodetection was performed as described in the ECL kit protocol (Amersham Pharmacia): blots were incubated for 2 h at room temperature with specific antibody, washed with PBS, and incubated for another 30 min at room temperature with the peroxidase-conjugated antibodies. Western-blot analysis was performed with Fas, FasL, caspase3, Bcl-2, Bax, bFGF, VEGF, and β-actin antibodies (Santa Cruz Biotechnology Inc). All experiments were performed in triplicate.

Statistical analysis

SPSS10.0 for Windows (SPSS Inc) was used to analyze the data and plot curves. Pearson’s chi square test and t-test were used to compare the statistical significance of the differences in data from the two groups. A level of P<0.05 was considered statistically significant.

Results

Effects of tumstatin peptides on proliferation of HUVEC-12 and SGC-7901 cells

In order to assess the selective inhibitory effect of tumstatin peptides on proliferation of endothelial cells and human gastric cancer cells, the MTT assay was used to measure the viabilities of HUVEC-12 and SGC-7901 cell lines after a 24-h treatment of tumstatin peptide 19 or peptide 21. The results show that peptide 19 significantly inhibited the proliferation of SGC-7901 cells. However, peptide 21 had little effect on the proliferation of SGC-7901 cells (Figure 1A). Peptide 21 potently suppressed proliferation of HUVEC-12 cells, whereas peptide 19 did not affect the proliferation of vascular endothelial cells (Figure 1B). Moreover, treatment with both peptides together resulted in a synergistic decrease of proliferation compared with the inhibitory effect of each peptide alone in both HUVEC-12 and SGC-7901 cell lines (P<0.05).

Effects of tumstatin peptides on cell apoptosis

After 48 h of treatment with peptides we observed an induction of apoptosis in SGC-7901 cells. We found that 13.3%±1.5% of the cells treated with peptide 19 alone and 17.7%±2.5%...
of the cells treated with peptide 19 and peptide 21 together underwent apoptosis, whereas only 4.7%±1.5% did so in the control peptide group. These differences were statistically significant (P<0.05). SGC-7901 control cells had the lowest rate of spontaneous apoptosis, 4.7%±1.5%, which rose to 7.3%±1.5% (P>0.05) after peptide 21 treatment as shown in Figure 2A–2E. We also noted a concurrent additive effect in the induction of apoptosis by treatment with peptide 19 and peptide 21 together in SGC-7901 cells. The rate of induced apoptosis increased by about 3.5-fold from 4.7%±1.5% (controls) to 17.7%±2.5%, whereas the use of each peptide alone was not as effective, as shown in Figure 2. We did not observe significant apoptosis in HUVEC-12 cells treated with tumstatin peptides (Figure 2F–2J).

Effects of tumstatin peptides on morphology of SGC-7901 cells and HUVEC-12 cells
Electron microscopy of SGC-7901 cells treated with peptide 19 alone or the combination of the two peptides showed typical apoptosis characterized by volume reduction, chromatin condensation, nuclear fragmentation, and the presence of apoptotic bodies (Figure 3B, 3D) when compared with the control cells (Figure 3A). These changes were not observed in SGC-7901 or HUVEC-12 cells after treatment with peptide 21 (Figure 3C, 3F, 3G, 3H).

Cell cycle assay
To study the effect of tumstatin peptide treatment on proliferation at different phases of the cell cycle, we treated exponentially growing cells with tumstatin peptides for 24 h. Conventional DNA FCM showed that 56.23% of the HUVEC-12 cells treated with control peptides were found in G0/G1 phase, 31.38% in S phase, and the remaining cells in G2/M phase. However, treatment with peptide 19, peptide 21, or the two peptides together resulted in an accumulation of cells in the G0/G1 phase. The fraction of G0/G1 DNA content accounted for 49.45% and 54.49% in the untreated SGC-7901 cells and control SGC-7901 cells. After treatment with peptide 19, peptide 21, or the two peptides together, the fraction of G0/G1 DNA content increased to 69.72%, 68.10%, and 69.78%, respectively, indicating that tumstatin peptides could arrest the cell cycle at the G0/G1 phase in both HUVEC-12 and SGC-7901 cells (Table 1).

Inhibition of tumor growth by tumstatin peptides in tumor-bearing mice
Treatment with peptide 19 or the combination of both pep-
tides yielded considerable inhibition of tumor growth (Figure 4). Significant tumor regression was observed at day 30 in animals treated with peptide 21 in the concentrations of 8.8 mg/kg \( (P<0.05) \). Treatment with the two peptides together had a synergistic inhibitory effect on tumor growth compared with treatment with either single peptide \( (P<0.05) \) (Table 2). All animals were alive until sacrifice, but 16% body weight loss occurred by day 20 after the peptide combination (4.4 mg/kg of each peptide) treatment. A 30% loss in body weight

Table 1. Effects of tumstatin peptides 19 and peptide 21 on the cell cycle distribution of SGC-7901 cells and HUVEC-12 cells by flow cytometry assay.

| Groups        | G1 (%) | G2 (%) | S (%) |
|---------------|--------|--------|-------|
| HUVEC-12      |        |        |       |
| Control       | 56.77  | 12.02  | 31.21 |
| Control peptide | 56.23 | 12.39  | 31.38 |
| Peptide 19    | 65.43  | 10.33  | 24.24 |
| Peptide 21    | 74.65  | 11.22  | 14.13 |
| Peptide 19+21 | 74.84  | 10.75  | 14.41 |
| SGC-7901      |        |        |       |
| Control       | 49.45  | 16.19  | 34.37 |
| Control peptide | 54.49 | 15.08  | 30.43 |
| Peptide 19    | 69.72  | 15.46  | 14.82 |
| Peptide 21    | 68.10  | 14.32  | 17.58 |
| Peptide 19+21 | 69.78  | 15.07  | 15.15 |

Table 2. Tumor volumes after treatment with peptide 19, peptide 21, or peptide 19 and peptide 21 together in orthotopic model (Tumor volumes: mean±deviation)

| Group           | Doses (mg/kg)                  | Tumor volums \( (\text{mm}^3) \) | t    | P       |
|-----------------|--------------------------------|----------------------------------|------|---------|
| Controls        |                                | 375.17±99.57                    |      |         |
| Control peptide | 4.4 mg/kg                      | 365.98±81.88                    | 0.362| 0.736   |
|                 | 6.6 mg/kg                      | 343.91±89.17                    | 0.789| 0.474   |
|                 | 8.8 mg/kg                      | 350.49±95.78                    | 0.344| 0.748   |
| Peptide 19      | 4.4 mg/kg                      | 257.09±45.44                    | 3.829| 0.019   |
|                 | 6.6 mg/kg                      | 183.72±26.28                    | 4.002| 0.016   |
|                 | 8.8 mg/kg                      | 69.96±14.93                     | 7.278| 0.002   |
| Peptide 21      | 4.4 mg/kg                      | 342.65±52.87                    | 0.469| 0.664   |
|                 | 6.6 mg/kg                      | 277.96±56.23                    | 1.928| 0.126   |
|                 | 8.8 mg/kg                      | 152.29±37.69                    | 5.250| 0.006   |
| Peptide 19+21   | 2.2 mg/kg+2.2 mg/kg            | 166.70±26.55                    | 4.424| 0.011   |
|                 | 3.3 mg/kg+3.3 mg/kg            | 113.93±24.52                    | 5.381| 0.006   |
|                 | 4.4 mg/kg+4.4 mg/kg            | 33.20±11.26                     | 7.253| 0.002   |

\( bP<0.05: \) compared with each control peptide.

Figure 3. SGC-7901 cells and HUVEC-12 cells treated with tumstatin peptides under electron microscope. A–D EM ×2500: SGC-7901 cell (A: control peptide; B: peptide 19; C: peptide 21; D: peptide 19 and peptide 21). E–H EM ×2500: HUVEC-12 cell (E: control peptide; F: peptide 19; G: peptide 21; H: peptide 19 and peptide 21). Arrows represent apoptotic bodies.

Figure 4. Tumstatin peptides inhibited gastric tumor growth in orthotopic model. (A) No treatment; (B) Treated with control peptide; (C) Treated with peptide 19 (8.8 mg/kg); (D) Treated with peptide 21 (8.8 mg/kg); (E) Treated with peptide 19 (4.4 mg/kg) and peptide 21 (4.4 mg/kg).
was observed with this treatment by day 30. In other groups, mice experienced <11% body weight loss.

Inhibition of angiogenesis by tumstatin peptides in tumor-bearing mice

We then examined the effect of tumstatin peptides on in vivo angiogenesis in tumors by immunostaining with CD34. Invasive growth of local cancer cells into lymph ducts was observed in control groups (Figure 5A). Tumors from animals receiving PBS (Figure 5B), control peptide, or peptide 19 (Figure 5C, 5D) showed intense CD34 staining, indicating the presence of extensive angiogenesis in the tumors. However, tumors from animals treated with peptide 21 alone or the combination of the two peptides together showed a significant reduction in microvessel density (Figure 5E, 5F) ($P=0.006$ and 0.001, respectively) (Table 3).

| Table 3. Density of microvessels in the tissues of orthotopic model (MVD: mean±deviation). |
|--------------------------------------|--------|------|
| Mean MVD                             | P      |
| Control                              | 22.2±3.6 | 0.448 |
| Control peptide                      | 20.0±2.6 | 0.352 |
| Peptide 19                           | 19.0±3.9 | 0.006 |
| Peptide 21                           | 8.8±2.4  | 0.001 |
| Peptide 19+21                        | 5.0±2.9  | 0.001 |

*P<0.05: compared with control.

Expression of Fas, Fasl, caspase 3, Bcl-2, Bax, VEGF, and bFGF in tumor tissues

26.67%, 13.33%, and 6.67% tumors were positive for Fas, Fasl, and caspase 3 in the mouse gastric cancer tissues treated with control peptide. However, 30 days after treatment with peptide 19 or the two peptides together, the expression levels of all three proteins increased in the gastric cancer tissues of mice (Figure 6A–6C). The expression of Fas, Fasl, and caspase 3 remained low in animals treated with peptide 21. The expression of Bcl-2 and Bax was similar in the three treated groups and the control peptide group (Figure 6D, 6E). The expression of VEGF and bFGF was high in the control peptide group and the peptide 19 group (Figure 6H, 6I). Treatment with peptide 21 (Figure 6F, 6G) or with the two peptides together decreased the expression of VEGF and bFGF in gastric cancer tissues (Table 4). We further confirmed these findings by Western blot analysis. The data showed that the expression levels of Fas, Fasl, and caspase3 were increased in mouse gastric cancer tissues treated with peptide 19 or peptide 19 and peptide 21, whereas the expression of Bcl-2 and Bax was similar in the three treated groups and the control peptide group (Figure 7).

Discussion

Angiogenesis, the process by which new blood vessels are derived from preexisting capillaries, is considered essential for tumor growth\cite{1, 19}. The tumor microenvironment influences the induction of tumor angiogenesis\cite{3, 19, 20}. The angiogenic switch is turned “on” when levels of endogenous angiogenesis stimulators, such as VEGF and bFGF, exceed those of endogenous angiogenesis inhibitors\cite{1, 5, 20, 21}. Tumstatin is one such endogenous angiogenesis inhibitor.

In the present study, we demonstrate the anti-tumor properties of two tumstatin synthetic peptides: peptide 19, which corresponds to residues 185–203 of the NC1 domain of the α3 [IV] chain, and peptide 21, a T7 mutant, in human gastric carcinoma cells in vitro and in vivo. We chose these two peptide fragments for tumor treatment because peptide 19 contains anti-tumor cell activity and we believed that peptide 21 would contain the anti-angiogenic property of tumstatin. Therefore, in combination with peptide 19, peptide 21 may have an adjuvant role in the treatment of gastric cancer. Peptide 19 inhibited proliferation and induced apoptosis in human gastric carcinoma cells. In contrast, peptide 21 specifically suppressed proliferation in endothelial cells, causing them to accumulate in G0/G1. Peptide 21 did not induce apoptosis in HUVEC-12 or SGC-7901 cells. In addition, peptide 19 and peptide 21 exhibited synergistic anti-tumor effects in vitro and in vivo. Our results confirmed that tumstatin synthetic peptide 19 selectively inhibited the proliferation of tumor cells, and tumstatin synthetic peptide 21 did not influence the growth or proliferation of tumor cells. None of the whole NC1 domains inhibited proliferation of cancer cell lines, as observed with
the 185-205(α3(IV)NC1) peptide (peptide 19), indicating that this effect is dependent on partial degradation of the NC1 domain\cite{22}.

This research also investigated the effect of these two peptide fragments on the growth of human gastric cancer xenografts in a mouse model. The animal model used in these gastric cancer experiments had the characteristics of orthotopic syngenic tumors (SGC-7901 cells) in an immunocompetent host (nude mice). Thus, the results from this study are clinically relevant. Our results show that peptide 19 suppressed the growth of tumor xenografts in a dose-dependent manner. However, peptide 21 suppressed the growth of tumor xenografts only at higher concentrations. These findings are consistent with previously reported results. Previous data showed that tumstatin delayed primary tumor growth and metastasis but failed to achieve tumor regression in animal models. Treatment with both peptide fragments caused some weight loss in the experimental animals, which was tolerable when less than 8.8 mg/kg peptide was used. Higher concentrations (over 8.8 mg/kg) of tumstatin were not used in this study because of high toxicity.

We observed in vivo that mice treated with peptide 21 had a lower number of CD34-positive vessels along with an impairment in angiogenesis. In vitro, we did not detect apoptotic endothelial cells in cells treated with peptide 21. These results indicate that peptide 21 selectively inhibits endothelial cells and induces apoptosis of new vessels in tumors, but does not affect normal endothelial cells.

CAO et al reported that a fusion peptide made of tumstatin-derived peptides a.a. 74–98 and a.a. 197–215 connected by the human IgG3 upper hinge region possesses antiangiogenic and antitumor cell proliferation properties. They showed that this peptide potently inhibited the proliferation of human endothelial (HUVEC-12) cells and human colon cancer (SW480) cells.

**Figure 6.** Immunohistochemical expression of Fas; FasL; caspase3; Bcl-2; Bax; VEGF and bFGF in orthotopic gastric carcinoma samples or orthotopic gastric carcinoma treated with peptide 19 and peptide 21. Plasma or membrane staining was frequently observed in tumour cells treated with peptide 19 (A, B, C, D, and E; Fas; FasL; caspase 3; Bcl-2 and Bax, respectively A×400, B×400, C×200, D×400, and E×200). Absent expression of bFGF (F×200) or VEGF (G×200) was observed in tumour cells treated with peptide 21. Expression of bFGF (H×200) and VEGF (I×400) were high in orthotopic gastric carcinoma samples without treatment.

**Figure 7.** (A) Western blot analysis showed that the expression levels of Fas, FasL, caspase 3 were upregulated in orthotopic gastric carcinoma tissues treated with peptide 19 or peptide 19 and peptide 21. (B) The histogram shows the results from applying Glyco Band-Scan software. (Control P: Control peptide; *P*<0.05 vs each control).
in vitro, with no inhibition of proliferation in Chinese hamster ovary (CHO-K1) cells. The peptide also significantly inhibited human endothelial cell tube formation and suppressed tumor growth of SW480 cells in a mouse xenograft model. The antiangiogenic activity of tumstatin is localized to two distinct integrin binding regions that are separate from the region responsible for its anti-tumor activity. α3β1 integrin binds to the NH2-terminal end, amino acids 54–132, which is presumably associated with cap-dependent translation inhibition and antiangiogenic activity. α3β1 integrin binds to the C-terminal region, residues 185–203, which is associated with antitumor activity. When tumstatin binds to αvβ3 integrin in endothelial cells it inhibits phosphorylation of FAK. Inhibition of FAK activation leads to inhibition of the FAK/PI-3K/Akt/mTOR/eIF4E/4E-BP1 signaling axis that mediates cap dependent translation, resulting in activation of apoptosis. The binding of α3(IV)NC1 to α3β1 integrin transdominantly inhibits αvβ3 expression in cells. Under hypoxic conditions, this inhibits NfxB mediated signaling and leads to inhibition of COX-2/VEGF/bFGF expression, resulting in inhibition of hypoxic tumor angiogenesis. We found that the expression of VEGF and bFGF was low in gastric cancer tissues of mice treated with peptide 21. Peptide 21 has no effect on apoptosis of tumor cells and may prevent angiogenesis by suppressing the activity of VEGF and bFGF. However, in gastric cancer tissues of mice treated with peptide 19 alone or peptide 19 and peptide 21 together, the expressions of Fas, FasL, and caspase3 were high. The expressions of Bcl-2 and Bax were similar between the treated and control groups. These results show that peptide 19 may induce apoptosis of tumor cells through the Fas pathway but not through the Bcl-2 family.

There are distinct mechanisms that mediate the antiangiogenic and anti-proliferative activities of these tumstatin peptides. The data reported here suggest that two tumstatin synthetic peptide fragments together facilitate two unique antitumor activities, which could make them valuable therapeutic agents for inhibition of tumor growth.

Acknowledgments

This work was supported by a grant from the National Natural Science Foundation of China (No 30472035), the Key Program of Heilongjiang Science and Technology Foundation (ZJY04-0102), Heilongjiang Innovation Program in Graduate Education (YJSCX2007-0201HLJ), a grant from the Department of Education of Heilongjiang Province (11531089), and the Youth Program of Heilongjiang Science and Technology Foundation (QC08C07).

Table 4. Expressions of Fas, FasL, Bcl-2, Bax, VEGF, bFGF, and caspase 3 in orthotopic gastric carcinoma tissues.

| Antibody | Control Positive (%) | Control peptide Positive (%) | Peptide 19 Positive (%) | Peptide 21 Positive (%) | Peptide 19 and 21 Positive (%) | P       |
|----------|----------------------|-----------------------------|------------------------|------------------------|-------------------------------|---------|
| Fas      | 20 (1/5)             | 26.67 (4/15)                | 80.0 (12/15)           | 0.031⁎                  | 6.67 (1/15)                   | 0.038b  |
| FasL     | 20 (1/5)             | 13.33 (2/15)                | 86.7 (13/15)           | 0.014⁣                 | 20.0 (3/15)                   | 0.038b  |
| Bcl-2    | 80 (4/5)             | 93.33 (14/15)               | 86.7 (13/15)           | 0.014⁣                 | 93.3 (14/15)                  | 0.038b  |
| Bax      | 40 (2/5)             | 27.77 (4/15)                | 40 (6/15)              | 1.000                  | 33.33 (5/15)                  | 0.038b  |
| VEGF     | 80 (4/5)             | 80 (12/15)                  | 86.7 (13/15)           | 0.031⁣                 | 13.3 (2/15)                   | 0.038b  |
| bFGF     | 80 (4/5)             | 73.33 (11/15)               | 73.3 (11/15)           | 0.031⁣                 | 13.3 (2/15)                   | 0.038b  |
| Caspase 3| 0 (0/5)              | 6.67 (1/15)                 | 60.0 (9/15)            | 0.038⁣                 | 6.7 (1/15)                    | 0.038b  |

⁎P<0.05: compared with each control peptide.
Maeshima Y, Manfredi M, Reimer C, Holthaus KA, Hopfer H, Chandamuri BR, et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 2001; 276: 15240–8.

Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, Kharbanda S, et al. Extracellular matrix-derived peptide binds to αvβ3 integrin and inhibits angiogenesis. J Biol Chem 2001; 276: 31959–68.

Han J, Ohno N, Pasco S, Monboisse JC, Borel JP, Kefalides NA. A cell binding domain from the α3 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem 1997; 272: 20395–401.

Monboisse JC, Garnotel R, Bellon G, Ohno N, Perreau C, Borel JP, et al. The α3 chain of type IV collagen prevents activation of human polymorphonuclear leukocytes. J Biol Chem 1994; 269: 25475–82.

Shahan TA, Fawzi A, Bellon G, Monboisse JC, Kefalides NA. Regulation of tumor cell chemotaxis by type IV collagen is mediated by a Ca2+-dependent mechanism requiring CD47 and the integrin α(3)β(1). J Biol Chem 2000; 275: 4796–802.

O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasiou G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–85.

Zhu B, Lu L, Cai W, Yang X, Li C, Yang Z, et al. Kallikrein-bindin protein inhibits growth of gastric carcinoma by reducing endothelial growth factor production and angiogenesis. Mol Cancer Ther 2007; 6: 3297–306.

Soares AB, Juliano PB, Araujo VC, Metze K, Altemani A. Angiogenic switch during tumor progression of carcinoma ex-pleomorphic adenoma. Virchows Arch 2007; 451: 65–71.

Folkman J, Kalluri R. Cancer without disease. Nature 2004; 427: 787.

Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003; 3: 422–33.

Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1: 120–2.

Sudhakar A, Boosani CS. Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression. Pharm Res 2008; 25: 2731–9.

Cao JG, Peng SP, Sun L, Li H, Wang L, Deng HW. Vascular basement membrane-derived multifunctional peptide, a novel inhibitor of angiogenesis and tumor growth. Acta Biochim Biophys Sin 2006; 38: 514–22.

Pedchenko V, Zent R, Hudson BG. Alpha(v)β3 and alpha(v)β5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the α3 chain of type IV collagen: implication for the mechanism of endothelial cell adhesion. J Biol Chem 2004; 279: 2772–80.

Boosani CS, Mannam AP, Cosgrove D, Silva R, Hodivala-Dilke KM, Keshamouni VG, et al. Regulation of COX-2 mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis. Blood 2007; 110: 1168–77.

Floquet N, Pasco S, Ramont L, Derreumaux P, Laronze JY, Nuzillard JM, et al. The antitumor properties of the α3(IV)-(185-203) peptide from the NC1 domain of type IV collagen(tumstatin) are conformation-dependent. J Biol Chem 2004; 279: 2091–100.